FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011782772> ?p ?o ?g. }

• W2011782772 endingPage "A93" @default.
• W2011782772 startingPage "A86" @default.
• W2011782772 abstract "We recently completed a double-blind, placebo-controlled, multicenter Phase III clinical trial of the pentavalent rotavirus vaccine (PRV) in three African countries, Ghana, Kenya, and Mali, from April 2007 to March 2009. The immunogenicity of PRV in African infants is described. In total, 5468 infants were randomized 1:1 to receive 3 doses of PRV or placebo at approximately 6, 10, and 14 weeks of age. Breastfeeding and concomitant administration of EPI vaccines, including OPV, were allowed, and HIV-infected infants were not excluded. Immunogenicity of PRV was assessed by measuring serum anti-rotavirus IgA responses, as well as serum neutralization antibody (SNA) to the human rotavirus serotypes G1, G2, G3, G4 and P1A[8] in approximately 150 infants per country. Sera were collected pre-dose 1 (pD1) and approximately 14 days post-dose 3 (PD3) for immunological analysis. For the sero-response rates (≥3-fold rise from pD1 to PD3), the number of subjects evaluable included those with both pD1 and PD3 data available. PRV was immunogenic in African children and significantly reduced severe RVGE in African children through the first two years of life. The pooled anti-rotavirus IgA sero-response rate was 78.3%, with consistent rates in each of the African sites: 73.8% (Kenya), 78.9% (Ghana), and 82.5% (Mali); but generally lower than that reported in Europe and USA. PD3 GMTs (28.2 dilution-units) were 5–10 times lower than those assessed in subjects in clinical trials in developed countries. SNA responses to human rotavirus serotypes G1–G4 and P1A[8] ranged from 6.3% (G3) to 26.5% (G4). PD3 SNA GMTs to G1 and P1A[8] were 4-fold and 3-fold lower respectively, when compared to the corresponding GMTs in subjects who received PRV in similar studies conducted in developed countries. PRV was immunogenic in African infants, and the anti-rotavirus IgA sero-response rates were similar across all three African sites although lower than those observed in Europe and USA. While immune correlates of protection have not been established for rotavirus, the findings are consistent with lower efficacy rates demonstrated during this trial. Further investigation is needed to understand the reason for the lower immunogenicity observed." @default.
• W2011782772 created "2016-06-24" @default.
• W2011782772 creator A5004383063 @default.
• W2011782772 creator A5022736839 @default.
• W2011782772 creator A5043479439 @default.
• W2011782772 creator A5051550648 @default.
• W2011782772 creator A5057901946 @default.
• W2011782772 creator A5062383257 @default.
• W2011782772 creator A5073330626 @default.
• W2011782772 creator A5074012686 @default.
• W2011782772 creator A5087954081 @default.
• W2011782772 creator A5090032482 @default.
• W2011782772 date "2012-04-01" @default.
• W2011782772 modified "2023-09-24" @default.
• W2011782772 title "Immunogenicity of the pentavalent rotavirus vaccine in African infants" @default.
• W2011782772 cites W1964472667 @default.
• W2011782772 cites W1965526538 @default.
• W2011782772 cites W1966419374 @default.
• W2011782772 cites W1974895422 @default.
• W2011782772 cites W1976924391 @default.
• W2011782772 cites W1989064407 @default.
• W2011782772 cites W2005036898 @default.
• W2011782772 cites W2009514184 @default.
• W2011782772 cites W2039347178 @default.
• W2011782772 cites W2042510009 @default.
• W2011782772 cites W2042674044 @default.
• W2011782772 cites W2051514059 @default.
• W2011782772 cites W2074761425 @default.
• W2011782772 cites W2082212577 @default.
• W2011782772 cites W2084653854 @default.
• W2011782772 cites W2092090915 @default.
• W2011782772 cites W2101381407 @default.
• W2011782772 cites W2128592628 @default.
• W2011782772 cites W2131154800 @default.
• W2011782772 cites W2137484598 @default.
• W2011782772 cites W2142473199 @default.
• W2011782772 cites W2143233237 @default.
• W2011782772 cites W2153862307 @default.
• W2011782772 cites W2163306701 @default.
• W2011782772 cites W2166083251 @default.
• W2011782772 cites W2170749337 @default.
• W2011782772 cites W4231603137 @default.
• W2011782772 cites W4236114911 @default.
• W2011782772 cites W4362206875 @default.
• W2011782772 doi "https://doi.org/10.1016/j.vaccine.2011.10.006" @default.
• W2011782772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22520142" @default.
• W2011782772 hasPublicationYear "2012" @default.
• W2011782772 type Work @default.
• W2011782772 sameAs 2011782772 @default.
• W2011782772 citedByCount "51" @default.
• W2011782772 countsByYear W20117827722012 @default.
• W2011782772 countsByYear W20117827722013 @default.
• W2011782772 countsByYear W20117827722014 @default.
• W2011782772 countsByYear W20117827722015 @default.
• W2011782772 countsByYear W20117827722016 @default.
• W2011782772 countsByYear W20117827722017 @default.
• W2011782772 countsByYear W20117827722018 @default.
• W2011782772 countsByYear W20117827722019 @default.
• W2011782772 countsByYear W20117827722020 @default.
• W2011782772 countsByYear W20117827722021 @default.
• W2011782772 countsByYear W20117827722022 @default.
• W2011782772 countsByYear W20117827722023 @default.
• W2011782772 crossrefType "journal-article" @default.
• W2011782772 hasAuthorship W2011782772A5004383063 @default.
• W2011782772 hasAuthorship W2011782772A5022736839 @default.
• W2011782772 hasAuthorship W2011782772A5043479439 @default.
• W2011782772 hasAuthorship W2011782772A5051550648 @default.
• W2011782772 hasAuthorship W2011782772A5057901946 @default.
• W2011782772 hasAuthorship W2011782772A5062383257 @default.
• W2011782772 hasAuthorship W2011782772A5073330626 @default.
• W2011782772 hasAuthorship W2011782772A5074012686 @default.
• W2011782772 hasAuthorship W2011782772A5087954081 @default.
• W2011782772 hasAuthorship W2011782772A5090032482 @default.
• W2011782772 hasConcept C10389963 @default.
• W2011782772 hasConcept C142724271 @default.
• W2011782772 hasConcept C159047783 @default.
• W2011782772 hasConcept C159654299 @default.
• W2011782772 hasConcept C187212893 @default.
• W2011782772 hasConcept C203014093 @default.
• W2011782772 hasConcept C204787440 @default.
• W2011782772 hasConcept C2522874641 @default.
• W2011782772 hasConcept C27081682 @default.
• W2011782772 hasConcept C2776283161 @default.
• W2011782772 hasConcept C2777227250 @default.
• W2011782772 hasConcept C2777451964 @default.
• W2011782772 hasConcept C2779416561 @default.
• W2011782772 hasConcept C2780868878 @default.
• W2011782772 hasConcept C2781367151 @default.
• W2011782772 hasConcept C71924100 @default.
• W2011782772 hasConceptScore W2011782772C10389963 @default.
• W2011782772 hasConceptScore W2011782772C142724271 @default.
• W2011782772 hasConceptScore W2011782772C159047783 @default.
• W2011782772 hasConceptScore W2011782772C159654299 @default.
• W2011782772 hasConceptScore W2011782772C187212893 @default.
• W2011782772 hasConceptScore W2011782772C203014093 @default.
• W2011782772 hasConceptScore W2011782772C204787440 @default.
• W2011782772 hasConceptScore W2011782772C2522874641 @default.
• W2011782772 hasConceptScore W2011782772C27081682 @default.

• next